Samsung Bioepis Pushes Stelara Rival Into Phase I
Proposed Ustekinumab Biosimilar Is Competing With Several Other Candidates
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.
You may also be interested in...
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.